We are Viapath

Following a year of growth in activity, revenue and profits, GSTS Pathology and KingsPath are now Viapath.

Building on our foundations of clinical and scientific excellence at Guy’s and St Thomas’ and King’s College Hospitals, two world-leading NHS Trusts, we continue our journey to build a network of the best minds. Working hand-in-hand with our clinicians, we aim to enable better outcomes for patients every day.

Majority owned by the NHS, we have the commercial freedom to invest in growth and innovation. The company is ambitious to grow, and is committed to the achievement of high clinical standards and high levels of operating efficiency in pathology services across the UK. Core to our mission is using its experience to enable other NHS organisations to transform their pathology services.

Richard Jones, CEO, Viapath, said: ‘Our record shows that transforming pathology services can lead to better services for clinicians and patients and deliver surpluses for investment. I am proud to lead a team of exceptional people – top scientists, clinicians, laboratory staff and business specialists. We have a clear vision of how our scientific and clinical knowledge translates into a market-leading portfolio of diagnostic tests and services – and a commitment to work in close partnership with hospital and community healthcare providers to improve the lives of patients, every day.’

The origins of the new Viapath organisation were set five years ago, when Guy’s and St Thomas’ NHS Foundation Trust and Serco plc formed GSTS Pathology as a joint venture. Later in 2009, GSTS won a contract to provide pathology services to Bedford Hospital NHS Trust. In 2010, King’s College Hospital NHS Foundation Trust became members of the joint venture. 

Now, with around 1,000 employees currently processing more than 22 million tests per annum, the work of Viapath touches thousands of lives every day.

PHOTOS: Launch day activities